Bioventus Inc. (NYSE:BVS) Shares Acquired by Jane Street Group LLC

Jane Street Group LLC increased its position in shares of Bioventus Inc. (NYSE:BVS) by 288.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 40,037 shares of the company’s stock after purchasing an additional 29,726 shares during the period. Jane Street Group LLC’s holdings in Bioventus were worth $478,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in BVS. Bank of New York Mellon Corp purchased a new position in shares of Bioventus during the 2nd quarter worth approximately $647,000. Rhumbline Advisers raised its position in Bioventus by 5,367.9% in the second quarter. Rhumbline Advisers now owns 52,437 shares of the company’s stock worth $302,000 after acquiring an additional 51,478 shares in the last quarter. Acadian Asset Management LLC raised its position in Bioventus by 403.1% in the second quarter. Acadian Asset Management LLC now owns 27,956 shares of the company’s stock worth $159,000 after acquiring an additional 22,399 shares in the last quarter. American Century Companies Inc. lifted its holdings in Bioventus by 289.5% in the second quarter. American Century Companies Inc. now owns 169,161 shares of the company’s stock valued at $973,000 after acquiring an additional 125,736 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of Bioventus by 100.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 117,496 shares of the company’s stock worth $676,000 after purchasing an additional 58,954 shares in the last quarter. Institutional investors and hedge funds own 62.94% of the company’s stock.

Wall Street Analysts Forecast Growth

BVS has been the subject of a number of research analyst reports. Craig Hallum increased their price target on shares of Bioventus from $12.00 to $17.00 and gave the company a “buy” rating in a report on Friday, September 27th. Canaccord Genuity Group increased their target price on shares of Bioventus from $12.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Finally, JPMorgan Chase & Co. raised Bioventus from an “underweight” rating to a “neutral” rating and boosted their price target for the stock from $12.00 to $13.00 in a research note on Tuesday, December 17th.

Insider Buying and Selling at Bioventus

In related news, CFO Mark Leonard Singleton sold 10,733 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $10.53, for a total transaction of $113,018.49. Following the transaction, the chief financial officer now owns 105,162 shares of the company’s stock, valued at approximately $1,107,355.86. This represents a 9.26 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Katrina J. Church sold 2,535 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $10.53, for a total transaction of $26,693.55. Following the sale, the senior vice president now owns 47,264 shares in the company, valued at approximately $497,689.92. This trade represents a 5.09 % decrease in their position. The disclosure for this sale can be found here. 32.90% of the stock is owned by insiders.

Bioventus Price Performance

Bioventus stock opened at $9.83 on Tuesday. The firm has a market capitalization of $797.75 million, a PE ratio of -16.11 and a beta of 0.85. Bioventus Inc. has a 52 week low of $3.90 and a 52 week high of $14.38. The firm’s 50-day simple moving average is $11.49 and its 200 day simple moving average is $10.03. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85.

Bioventus (NYSE:BVS) last announced its quarterly earnings results on Tuesday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.06. Bioventus had a negative net margin of 7.11% and a positive return on equity of 15.61%. The company had revenue of $138.96 million for the quarter, compared to the consensus estimate of $132.57 million. During the same quarter in the prior year, the firm earned $0.05 earnings per share. On average, equities research analysts predict that Bioventus Inc. will post 0.41 EPS for the current fiscal year.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.